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ABSTRACT
Wound infections are a serious medical problem for 
patients with non-healing chronic wounds and burn injuries. 
The healing of these wounds is often compromised by 
colonisation of many different bacteria, predisposing patients 
to life-threatening infections. Infected wounds continue to 
represent a complex problem for both health professionals 
and patients. Bacterial infections are a critical component 
of hard-to-heal wounds, often leading to biofilm formation, 
inhibition of innate inflammatory responses and resistance to 
traditional therapeutics. Over the last 20 years, tremendous 
progress has been made in understanding the intricacies 
of wound biofilm pathology and bacteria–host interactions. 
This has been achieved by the development of in vitro and in 
vivo models of wound infection. This review will discuss the 
challenges in the development of wound infection models 
and will focus on different in vivo models of cutaneous wound 
infection, highlighting advantages and clinical applicability of 
each model. It will also describe the development of novel 
bioluminescent models of cutaneous wound infection in vivo, 
which may help to revolutionise the future testing of novel 
antimicrobial therapeutics for the treatment of wounds.
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INTRODUCTION
Chronic wounds represent a silent epidemic affecting a 
substantial portion of the global population and place a 
significant economic burden on the healthcare system. In 
Australia alone, chronic wound treatments are estimated 
to cost over $2.85 billion annually1. These estimates are 
often understated, and do not include the impact on patient 
lifestyle, financial security and overall wellbeing, which 
collectively place an immeasurable burden on these most 
vulnerable people. Despite the significant progress that has 
been made in understanding chronic wound infections and 
the improved treatment modalities, the incidence of infected 
chronic wounds is still on the rise, in part due to the growing 
rate of other chronic diseases that can impact on wound 
healing, including obesity, diabetes mellitus, and perivascular 
disease2.
Human skin provides a formidable barrier to environmental 
pathogens; however, in patients with chronic wounds, burn 
injuries, the elderly, and those suffering from skin blistering 
diseases, including epidermolysis bullosa (EB), there is 
impairment to the skin’s barrier and often a compromised 
immune system, which leads to severe infection and sepsis3. 
Effective management of infection in chronic wounds 
focuses on aggressive debridement of devitalised tissue 
and control of patient co-morbidities that may further delay 
wound healing as well as the use of systemic antibiotics in 
the presence of cellulitis; however, these approaches are 
often not successful4. Furthermore, studies have shown that 
between 55% and 80% of patients admitted to burn units 
develop hospital-acquired infections4. In addition, sepsis is 
the leading cause of infant mortality in patients with different 
EB subtypes and up to 24% of patients with junctional EB die 
from sepsis by 15 years of age5. Alarmingly, infection of skin 
wounds by pathogenic bacteria that are resistant to multiple 
classes of antimicrobials accounts for massive morbidity 
and mortality in humans worldwide and the development of 
new antimicrobials is hampered by a lack of technologies 
aimed at preclinical assessment of novel therapies that might 
combat infections and bacterial biofilm formation6.
The lack of adequate in vivo models of wound infection has 
made it difficult to investigate bacterial wound infections6. 
As human studies are logistically and ethically prohibitive, 
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the use of animal models for preclinical testing of new 
localised or systemic therapies is the best approach to treat 
the problem of chronic wound infection. An established 
theory of modern medicine is that no in vitro, in situ or in 
silico model can adequately account for the complex host 
defence mechanisms and interactions between a host and 
a pathogen that is encountered in a live animal model7. 
Developing an in-depth understanding of bacterial biofilms, 
infections and potential therapeutic treatments requires in 
vivo models that can be utilised to understand the complex 
interactions between the bacteria and the host, while 
overcoming the challenges of strain diversity and differences 
between local and systemic infection manifestations7.
This review will describe some of the most common and 
latest in vivo models of cutaneous wound infection under 
development, focusing on Streptococcus pyogenes (S. 
pyogenes) and Staphylococcus aureus (S. aureus) as 
examples of some of the most common bacteria encountered 
in patients with chronic wounds8. Advances in technologies 
have allowed the development of in vivo models to become 
more sophisticated and these novel models will also have a 
direct impact on our understanding and treatment of infected 
human wounds.
CHALLENGES IN DEVELOPING WOUND 
INFECTION AND BIOFILM MODELS
Bacterial biofilms have an inherent defence and survival 
mechanism that includes: avoidance of host inflammatory 
cells, resistance to antibiotics, and dynamic cell to cell 
communication pathways, all of which allow their continuing 
presence in non-healing wounds2. The moist and nutritionally 
supportive microenvironment of the wound bed matrix is ideal 
for the formation of bacterial biofilms, creating a destructive 
and sustainable environment which impairs wound repair2. 
Studies have demonstrated that the presence of a biofilm 
and bioactive compounds secreted by bacteria inhibit key 
wound healing mechanisms including cell proliferation and 
migration6. The presence of bacteria in chronic, hard-to-
heal wounds, has been confirmed by both imaging and 
more sophisticated molecular sampling techniques which 
shows that the amount of bacteria in a wound is often 
underestimated and that most often wounds contain a mixed 
population of multiple bacterial species2. These bacterial 
biofilms present a major obstacle in the development of 
wound infection models that represent infection of chronic 
human wounds both histologically and immunologically.
MODELS OF CUTANEOUS WOUND INFECTION
The infected subcutaneous ulcer/air sac model is one of the 
most widely used models for the analysis of S. pyogenes 
and other streptococci that results in localised inflammatory 
lesions with robust levels of bacteria cell proliferation and 
inflammatory cell recruitment7. In this model, 106–108 CFU 
(colony forming units) of the S. pyogenes strain of interest 
are injected into tissue, which results into a well-defined area 
of infection by 8–12 hours post infection. The lesion formed 
Figure 1: Murine subcutaneous ulcer model of wound 
infection
Representative histological Haematoxylin and Eosin stained 
images of S. pyogenes HSC5 infection at day 1 and day 3 post 
infection following subcutaneous inoculation of 1x106 CFUs into 
flank skin of SKH1 mice. Uninfected control section illustrates 
the histological differences and the development of the infected 
ulcer in these mice SKH1 mice. By day 1 of inoculation, a well-
defined subcutaneous lesion is formed consisting of a necrotic 
core containing the bacteria and a margin infiltrated with 
inflammatory cells. E = epidermis. D = dermis, PC = panniculus 
carnosus. F = fascia. M = muscle. Magnification = 40x. White 
dotted line = lesion margin, black dotted line = abscess/wound 
outline, black arrows = inflammatory cell infiltrate. Figure 
adapted from reference 7 and modified with permission. 
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is infiltrated by neutrophils and leads to formation of an 
abscess, which by 18–24 hours post-infection ulcerates and 
develops a wound covered by an eschar (Figure 1)7. By day 
8 the lesion begins to resolve and by day 14 the wound is 
healed. This model has been widely used in different strains 
of mice including BALB/c, C57BL6 strains and many other 
transgenic and knock-out variants7.
One of the challenges of this model is that the ulcer will have 
an irregular border. This makes the model more relevant to 
human infected wounds; however, it makes the scientific 
conclusions about healing rate and bacterial virulence hard 
to interpret. However, useful parameters of assessment 
include changes in weight, numbers of CFUs that are 
recoverable from the wound and numbers of mice that do 
not develop an infection or ulcer, as well as time to maximum 
ulcer area and time to healing of the resulting wound7. The 
air sac model is an extension of this model whereby an air 
pouch is initially created under the skin by injection of air 
prior to infection and bacteria are subsequently injected into 
this air sac. The advantage of this model is that it allows 
researchers to recover host inflammatory cells for analysis 
by lavage compared to the subcutaneous ulcer model7. 
A disadvantage of these two models is that they do not 
histologically reproduce some of the features of human 
cutaneous disease including impetigo, pyoderma, cellulitis 
or necrotising fasciitis7. These differences are attributed to 
the anatomical differences between a mouse and human 
skin, with mouse skin having a significantly higher density 
of hair follicles; as well as variations in bacterial virulence 
between species9. Clear strengths of this model, however, 
include simplicity, high-throughput and low cost, and ability 
to use mice of different genetic backgrounds. In addition, 
as bacteria grow in a defined wound-like environment it 
reproduces the dynamic host environment that is remodelled 
by both host immunity and bacterial metabolism10.
The impetigo model of superficial wound-like infection is 
also a popular model used to study superficial infections 
of the skin11. In this model, humanised mice are created by 
grafting human epidermal tissue from neonatal foreskin onto 
the flanks of immune-compromised SCID mice which are 
known to have no adaptive immune responses, meaning 
that the graft is not rejected. The engrafted tissue is then 
superficially wounded using cross-wise cuts with a scalpel 
blade. Bacteria, typically S. pyogenes, are then added 
Figure 2: Novel bioluminescent model of excisional wound infection
A–C  IVIS Lumina XRMS Series III Live Animal BioPhotonic imaging system (Caliper LifeSciences) allows for accurate and sensitive 
detection of live, actively metabolising bacteria in a high range of dilutions and individual growing bacterial colonies.
D–E Representative image of relative luminescence and total flux of S. aureus-infected excisional wounds on back of wild-type 
BALB/c mice over a period of seven days allowing for live in vivo assessment of wound infection and/or preclinical testing of 
antimicrobial agents. While bacterial load decreases after day 0 of inoculation, the bioluminescent signal is consistent over a period of 
seven days and sensitive enough to reflect even small changes in the bacterial infection load of wounds in vivo.
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to the superficial wounds, which are then occluded with 
a dressing11. This results in a superficial wound infection 
with erosion of the stratum corneum and infiltration of 
murine polymorphonuclear lymphocytes, leading to pus 
formation11. Virulence is measured by a semi-quantitative 
visual assessment of the histopathology or by determining 
the number of CFU to monitor bacterial growth. The extent of 
damage has been shown to correlate with the magnitude of 
streptococcal growth11. The limitations of this model include 
the high technical skill required to conduct the model as well 
as a source of human tissue. In addition, while the human 
skin is infected in this model, it still lacks human-specific 
targets of important virulence factors7.
Excisional wound infection models have been widely 
studied in models of S. aureus cutaneous infection. S. 
aureus is a commensal bacteria of the human skin, nares 
and gastrointestinal tract; however, it is also a leading 
cause of cutaneous wound infections, bacteraemia, sepsis, 
pneumonia and endocarditis12. Therapeutic options for both 
cutaneous and invasive S. aureus infections are becoming 
limited due to rising antimicrobial resistance, hence testing 
of new antimicrobial agents using relevant animal models 
is particularly important13. The pathological hallmark of S. 
aureus infection is the formation of an abscess or lesion. This 
was originally demonstrated by Ogston and colleagues, who 
isolated the pus from a surgical wound infection and showed 
that its injection into subcutaneous tissue of experimental 
animals led to abscess formation in guinea pigs and 
mice14. Most S. aureus cutaneous wound infections models 
today focus on developing infection in excisional wounds 
topically; however, original models involved inducing the skin 
infection in mice by injecting a suspension of 107–109 CFU 
S. aureus subcutaneously. Within 24 hours, bacteria elicit an 
inflammatory response and cause localised swelling, which, 
over a time course of 5–7 days, can become 30–100 mm2 
in size15. Abscess lesions can rupture and become an open 
wound or may be resolved over a 7–9 day period. Depending on 
the strain of S. aureus and the production of the α-haemolysin 
(α-toxin), subcutaneous lesions can be associated with 
superficial dermonecrosis, which heals at a similar rate to the 
resolution of the abscess lesion16,17. This model of cutaneous 
skin infection is often modified to examine the contribution 
of specific skin cells or tissue structures and immune cells. 
This model has also evolved to include inducing damage to 
the skin, that is, removal of superficial keratinocytes, creation 
of a full-thickness excisional wound using a punch biopsy 
(6 mm2) and creation of a full-thickness incisional wound or 
burn injury using heat. These wounds are then inoculated 
with 107–109 CFU of bacteria to induce infection4. In addition, 
some protocols involve inoculating the bacteria along with 
implanted foreign material (suture, dextran beads, cotton 
dust), allowing researchers to examine the effects of bacterial 
infection in different wound environments and reduce the 
pathological dose of bacteria required to cause a pathological 
lesion17,18. Along the same lines as wound infection mouse 
Figure 3: Novel bioluminescent model of burn injury wound infection
Schematic illustration of cutaneous burn injury wound infection model using a bioluminescent strain of Pseudomonas aeruginosa. 
The luminescent bacteria are continuously monitored between the treatments and over a period of time and the viable count is 
analysed in the wound as well as inner organs at the end of the study. Assessment of the bacterial load in blood and organs allows for 
monitoring of systemic sepsis development, which can occur depending on the type of bacteria and amounts of CFUs used in wound 
inoculations. Figure adapted from reference 4 with permission.
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models, inoculation of partial-thickness wounds in pigs with 
S. aureus results in the formation of biofilm-like structures 
only 48 hours post-inoculation19. In addition, mouse models 
of S. aureus infection of surgically implanted medical devices 
and catheters have been developed20,21. The most popularly 
used one is the implanted chamber model often used in mice 
and rabbits22-24.
Biofilm formation is a hallmark of chronic wound infection, 
and establishment of a good chronic wound model of 
infection is controversial and dependent on the research 
question. Besides inflicting a wound, maintaining a biofilm 
infection within a model for a certain period of time to classify 
the model as a chronic wound model remains challenging. 
Studies have attempted to address this problem by using 
different approaches, including: use of preconditioned animals 
(mutant breeds or by induction of a pathogenesis, for example 
diabetes25, preformation of the biofilm in vitro prior to wound 
inoculation26, or placement of a dressing material to maintain 
the wound moisture and facilitate biofilm formation27. In these 
models, utilising a well-described model of streptozotocin-
induced diabetes, infection was caused in excisional wounds 
of diabetic mice by inoculation with ~107 CFUs of exponential 
phase S. aureus which were allowed to grow for 48 hours. 
Signs of chronic wound infection including purulent discharge, 
redness and swelling were subsequently observed28.
To achieve more clinically relevant chronic wound models 
of infection, studies have also tried to address the problem 
of contraction, by using dressings as a mechanical barrier 
to wound contraction in streptozotocin-induced diabetic 
mice with excisional full-thickness infected wounds29,30. 
Additionally, a rabbit dermal ulcer model has been 
developed, whereby full-thickness dermal wounds which 
closely resemble human chronic wounds and the underlying 
cartilage acts as a natural splint preventing contraction and 
allowing healing by epithelisation and granulation31,32. Finally, 
a recent study has developed a chronic wound infection 
model using alloxan (a thiol reagent) to induce insulin-
dependent diabetes mellitus in New Zealand rabbits which 
were subsequently subjected to dorsal wounds inoculated 
with a mixed bacterial suspension of S. aureus and P. 
aeruginosa33. Wound chronicity was assessed at day 5 post 
inoculations by measurement of excessive inflammation and 
infection accompanied by clinical signs of chronic wound 
infection, namely exudate formation, wound degradation, 
epithelial bridges, discolouration of the wound bed, abscess 
formation and bad odour33.
NEW IMAGING METHODS FOR ANALYSING 
WOUND INFECTION
Improved visualisation and advanced imaging techniques 
have allowed the development of novel models of chronic 
wound infection with particular focus on “real-time” 
monitoring of the severity of infection and biofilm formation4. 
In addition, the development of bacterial strains engineered 
to be constitutively bioluminescent (mostly by insertion of 
the luxCDABE operon from Photorhabdus luminescens and 
Vibrio harveyi) have further enabled the development of novel 
models of wound infection. Bacterial luciferase operon can 
also be used for these applications as it is engineered for 
constitutive light emission at 490 nm12. Combined with the 
development of highly sensitive imaging procedures, it allows 
for direct and continuous monitoring and quantification of 
bacterial biofilm infections, by quantification of radiance 
levels, over a period of time, either using full-thickness 
wound injury (Figure 2), partial-thickness burn injury (Figure 
3)4 or subcutaneously implanted catheters34 and surgical 
meshes35. A recent study using FVB/N mice investigated 
the effect of using a breathable dressing, allowing oxygen in 
and moisture vapour out, on excisional wounds inoculated 
with a mixed population of bioluminescent methicillin-
resistant S. aureus and P. aeruginosa (107 CFU), on biofilm 
development, mimicking a clinically relevant chronic wound 
Figure 4: Use of wound dressing creates a better 
environment for development of more clinically relevant 
biofilm infected wounds in vivo
Top panel shows a visual representation of biofilm formation in 
excisional wounds infected with mixed population of S. aureus 
and P. aeruginosa covered with a TegadermTM dressing over 
a five-day period. Bioluminescent radiance as a measure of 
bacterial wound infection was analysed over a five-day period 
in: (A) covered non-treated infected wounds; (B) P. aeruginosa 
infected Rosa Bengal treated wounds; (C) S. aureus infected 
TLD1411 treated wounds; (D) uncovered non-treated infected 
wounds. Use of wound dressings in (A) clearly facilitates 
development of more chronic infection environment compared 
to uncovered infected wounds presented in (D). This model 
is useful for preclinical assessment of different antimicrobial 
treatments as shown in (B) and (C). Figure adapted from 
reference 36 with permission. 
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environment36. This study demonstrated that the use of 
a dressing allows development of a dense, mucous-like 
biofilm formation bulging the dressing outward, correlating 
with higher infection load and higher bioluminescent signal 
compared to uncovered wounds (Figure 4)36. In this model, 
the use of a wound dressing did not interfere with the 
detection of the bioluminescent signal and this model, while 
not in a physiologically chronic state (for example diabetes), 
offers a constant, longer lasting local wound infection 
consistent with chronic wounds, without the spontaneous 
clearing of bacteria that occurs when the wound dries out36.
One of the main advantages of in vivo models of wound 
infection using bioluminescent strains of bacteria is that 
these models allow for daily or twice-daily monitoring of 
bacterial load by visualisation of bacteria in live animals. This 
temporal or spatial monitoring of the progression of infection 
offers a significant advantage over more traditional models 
and uses fewer animals and experimental time points37. 
Bioluminescent models of wound infection allows in vivo 
imaging, whole organ studies and can be used to quantify 
viable wound bacterial burden up to seven days post-
infection (Figure 3). Importantly, the measure of radiance 
and total flux bioluminescence using the IVIS Lumina XRMS 
Series III Live Animal BioPhotonic imaging system or similar 
imaging systems closely correlates with the rate of wound 
healing and bacterial CFU counts obtained at end time 
points (Figure 2). Bioluminescent models of in vivo wound 
infection also uses bacteria that are stably luminescent 
even in the absence of antibiotic selection37. An additional 
advantage of these bioluminescent models is that they allow 
the unprecedented preclinical testing of novel antimicrobials 
(Figure 5). Additionally, there are now increasing numbers 
of different bacterial strains commercially available at an 
Figure 5: Use of bioluminescent models of wound infection for preclinical testing of novel antimicrobials
Excisional punch biopsy wounds were created on the back of Balb/c mice and inoculated with bioluminescent S. aureus (1x106 
CFUs) on day 0 of the experiment. IVIS Lumina XRMS Series III Live Animal BioPhotonic imaging system was used for daily analysis 
of the bacterial burden and treatment with test antimicrobial started on day 2 of the experiment. Representative images of relative 
luminescence and total flux of S. aureus infected excisional wounds analysed illustrate the benefits of using this model for preclinical 
testing of novel antimicrobials. Control uninfected mice have background levels of signal detection, highlighting the sensitivity of the 
system model used which needs to be considered when designing experiments.
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affordable price, allowing researchers to utilise these models. 
The only disadvantage of these models is the requirement 
of an expensive biophotonic imaging system which can 
cost in excess of $400,000. Nevertheless, these novel and 
reproducible models of wound infection allow the monitoring 
of wound infection in vivo over a seven-day period and 
facilitate the testing of antimicrobial compounds on their 
ability to treat wound infection.
CONCLUSION
Chronic wound infections represent a significant health and 
financial burden to both patients and health service providers. 
Developing new approaches and therapeutics to kill bacteria 
but not damage the wound tissue is important. Several 
models of wound infection exist and through the advent of 
bioluminescent bacteria and new imaging technologies, the 
real-time assessment of the development and treatment of 
infection and biofilm formation is becoming possible. In vivo 
animal models of wound infection are a valuable research 
tool that will aid our understanding of the pathogenesis of 
bacteria and biofilm formation as well as help the preclinical 
assessment of potential new wound treatments.
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REDUCTION IN CHRONIC WOUND PAIN 
REDUCTION OF BACTERIAL BURDEN1
KENDALL™ AMD 
ANTIMICROBIAL FOAM DRESSINGS 
WITH PHMB (POLYHEXAMETHYLENE BIGUANIDE HCI)
1: Sibbald RG, et al. AdvSkin Wound Care 2011;24(2): 78-84
Results of the trial suggests PHMB impregnated foam 
dressing as a viable option for the treatment of critically 
colonised chronic wounds.
